The size of the Europe Protein Therapeutics market was worth USD 39.98 billion in 2020. It is further expected to grow at a CAGR of 6.3% and value USD 54.27 billion by 2025. It captures 25% of the global market.
Protein therapeutics are most often employed in the treatment of chronic ailments like cancer etc. This market has huge potential in the coming years.
An increasing number of people suffering from chronic diseases coupled with rapid advancements in the medical sciences resulting in the development of plasma-based therapies are driving the growth of this market.
On the other hand, vague government policies and cumbersome administrative framework conjoined with the heavy cost of this treatment are inhibiting the market growth.
This research report on the European protein therapeutics market has been segmented and sub-segmented into the following categories:
By Product:
By Application:
By Therapeutic Modalities:
By Country:
In 2019, Monoclonal antibodies captured the largest market share. It is projected to remain the top leading segment in the forecast period. It is also the market sub-segment that is anticipated to undergo the fastest growth by 2025.
However, the cancer market sub-category is predicted to grow the fastest in the forecast period. It is the second-largest market lead by the UK.
Key players operating in the Europe Protein Therapeutics Market profiled in this report are Baxter International Inc., Eli Lilly, and Company, Abbott Laboratories, Amgen Inc., F. Hoffmann-La Roche Ltd. Other players in the market are Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and Sanofi.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Monoclonal Antibodies
5.1.3 Insulin
5.1.4 Fusion Protein
5.1.5 Erythropoietin
5.1.6 Interferon
5.1.7 Human Growth Hormone
5.1.8 Follicle Stimulating Hormone
5.1.9 Y-o-Y Growth Analysis, By Product
5.1.10 Market Attractiveness Analysis, By Product
5.1.11 Market Share Analysis, By Product
5.2 Therapeutic Modalities
5.2.1 Introduction
5.2.2 Protein diagnostics
5.2.3 Protein vaccines
5.2.4 Protein therapeutics with special targeting activity
5.2.5 Protein therapeutics with enzymatic or regulatory activity
5.2.6 Y-o-Y Growth Analysis, By Therapeutic Modalities
5.2.7 Market Attractiveness Analysis, By Therapeutic Modalities
5.2.8 Market Share Analysis, By Therapeutic Modalities
5.3 Application
5.3.1 Introduction
5.3.2 Metabolic Disorders
5.3.3 Immunologic Disorders
5.3.4 Hematological Disorders
5.3.5 Cancer
5.3.6 Hormonal Disorders
5.3.7 Genetic Disorders
5.3.8 Others
5.3.9 Y-o-Y Growth Analysis, By Application
5.3.10 Market Attractiveness Analysis, By Application
5.3.11 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Therapeutic Modalities
6.1.3.4 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Therapeutic Modalities
6.1.4.4 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Therapeutic Modalities
6.1.5.4 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen Inc.
8.3 Baxter International Inc.
8.4 Eli Lilly and Company
8.5 F. Hoffmann-La Roche Ltd.
8.6 Johnson & Johnson
8.7 Merck & Co. Inc.
8.8 Novo Nordisk A/S
8.9 Pfizer Inc.
8.10 Sanofi
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
